Clinical trial · Interventional
Treatment of Tumors of the Choroid Plexus Epithelium
A Pilot Study Evaluating the Feasibility of an Intercontinental Phase III Chemotherapy Study for Patients With Choroid Plexus Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): PI has left the institution
Summary
Brief summary (as posted)
The goal of this clinical research study is to compare carboplatin to cyclophosphamide when given with etoposide, vincristine, and radiation therapy in the treatment of choroid plexus tumors. The safety of these 2 combination therapies will also be compared. Objectives: OVERALL AIM: To improve choroid plexus tumor treatment through better understanding of the tumor biology and through increased knowledge about the benefit of specific treatment elements. Specific Objectives: The study will have a prephase to evaluate the feasibility of the following randomized study (main phase). Pre-Phase (completed 2005) Primary Specific Objective: To determine the number of patients accountable per year for randomization in a worldwide study. Secondary Specific Objective: To measure the number of drop outs and to describe the toxicity of the chemotherapy. Main Phase (started in 2006) Primary Specific Objective: To compare the survival times after cyclophosphamide based treatment with the survival times after carboplatin based treatment in choroid plexus tumor patients. Main Phase Secondary Specific Objectives: 1. To compare the resectability of choroid plexus tumors after two blocks of cyclophosphamide based treatment with the resectability after two blocks of carboplatin based treatment. 2. To compare response rates of incompletely resected choroid plexus tumors to two blocks of cyclophosphamide based treatment with the response rates after two blocks of carboplatin based treatment. 3. To determine the prognostic relevance of histological atypia and SV40 in choroid plexus tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Choroid Plexus Tumors | Choroid Plexus Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Carboplatin | Drug | Carboplatin | ALIAS |
| Cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| Etoposide | Drug | Etoposide | ALIAS |
| Radiation Therapy | Radiation | — | UNRESOLVED |
| Vincristine | Drug | Vincristine | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Carboplatin + Etoposide + Vincristine
- description
- Carboplatin 350 mg/m\^2 by vein, Over 2 Hours x 2 Days. Etoposide 100 mg/m\^2 by vein, Over 1 Hour x 5 Days. Vincristine 1.5 mg/m\^2 (by vein)IV Push Over 15 Minutes On Day 5. Radiation treatment over a period of about 6 weeks.
- interventionNames
- Drug: Carboplatin
- Drug: Etoposide
- Drug: Vincristine
- Radiation: Radiation Therapy
- type
- EXPERIMENTAL
- label
- Cyclophosphamide + Etoposide + Vincristine
- description
- Cyclophosphamide 1 g/m\^2 by vein, Over 1 Hour x 2 Days. Etoposide 100 mg/m\^2 by vein, Over 1 Hour x 5 Days. Vincristine 1.5 mg/m\^2 (by vein)IV Push Over 15 Minutes On Day 5. Radiation treatment over a period of about 6 weeks.
- interventionNames
- Drug: Cyclophosphamide
- Drug: Etoposide
- Drug: Vincristine
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. The reference center has confirmed the receipt of slides sent (For randomization only = form 2) 2. The postoperative imaging has been done and the result is available (for randomization only = for form 2 only) 3. Indication criteria: Choroid plexus papilloma (Gr I) with histologically confirmed metastases. (For randomization only = use form 2). 4. Indication criteria: Atypical choroid plexus papilloma or anaplastic choroid plexus papilloma histology with either metastases or postoperative residual tumor. (For randomization only = use form 2). 5. Indication criteria: Choroid plexus carcinoma, regardless of histologically confirmed metastases or residual tumor. (For randomization only = use form 2). 6. Informed consent signed (required for registration = form 1, and for randomization = form 2) 7. Patients must have the following: WBC \> 2000/ul, platelets \>85 000/ul, serum creatinine in normal range, pregnancy test negative, hearing loss less than 30dB at 3000 Hz. Exclusion Criteria: 1. Previous irradiation or chemotherapy. (Exclusion from randomization only) 2. The protocol did not pass the local centre required approvals, such as the Ethics Committee or the scientific review. 3. Previous immunotherapy or antiangiogenic therapy (Exclusion from randomization only)
References
Publications (1)
- DERIVEDWrede B, Hasselblatt M, Peters O, Thall PF, Kutluk T, Moghrabi A, Mahajan A, Rutkowski S, Diez B, Wang X, Pietsch T, Kortmann RD, Paulus W, Jeibmann A, Wolff JEA. Atypical choroid plexus papilloma: clinical experience in the CPT-SIOP-2000 study. J Neurooncol. 2009 Dec;95(3):383-392. doi: 10.1007/s11060-009-9936-y. Epub 2009 Jun 20. PMID 19543851